Dr. Chablaney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
240 E 38th Street
23rd Floor
New York, NY 10016Phone+1 212-263-3095Fax+1 212-263-3096
Education & Training
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Gastroenterology, 2019 - 2022
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2016 - 2019
- George Washington University School of Medicine and Health SciencesClass of 2016
Certifications & Licensure
- NY State Medical License 2018 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Publications & Presentations
PubMed
- 40 citationsShorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid Faleck, Adam Winters, Shreya Chablaney, Preeti Shashi, Joseph Meserve
Clinical Gastroenterology and Hepatology. 2019-11-01 - 44 citationsDevelopment and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.Parambir S. Dulai, Siddharth Singh, Niels Vande Casteele, Joseph Meserve, Adam Winters
Clinical Gastroenterology and Hepatology. 2020-02-13 - 31 citationsComparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.Dana J. Lukin, David Faleck, Ronghui Xu, Yiran Zhang, A Weiss
Clinical Gastroenterology and Hepatology. 2020-10-08
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: